JP2003192590A - 抗癌剤 - Google Patents
抗癌剤Info
- Publication number
- JP2003192590A JP2003192590A JP2001394637A JP2001394637A JP2003192590A JP 2003192590 A JP2003192590 A JP 2003192590A JP 2001394637 A JP2001394637 A JP 2001394637A JP 2001394637 A JP2001394637 A JP 2001394637A JP 2003192590 A JP2003192590 A JP 2003192590A
- Authority
- JP
- Japan
- Prior art keywords
- altocarpine
- anticancer agent
- group
- formula
- anticancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 125000002252 acyl group Chemical group 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 16
- 230000001093 anti-cancer Effects 0.000 abstract description 8
- 201000011510 cancer Diseases 0.000 abstract description 7
- 208000000453 Skin Neoplasms Diseases 0.000 abstract description 4
- 201000000849 skin cancer Diseases 0.000 abstract description 4
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960005243 carmustine Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000218232 Artocarpus Species 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- 102000001779 3-oxo-5-alpha-steroid 4-dehydrogenase Human genes 0.000 description 1
- 108010029908 3-oxo-5-alpha-steroid 4-dehydrogenase Proteins 0.000 description 1
- ZGMLACURZVGTPK-UHFFFAOYSA-N 5-fluoranyl-1h-pyrimidine-2,4-dione Chemical compound OC1=NC=C(F)C(O)=N1.FC1=CNC(=O)NC1=O ZGMLACURZVGTPK-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)CCC(C(C1C(O)=CC(*)=C=C1)OC(CC(*)=C1CCC(C)C)C2C1O*)C2=O Chemical compound CC(C)CCC(C(C1C(O)=CC(*)=C=C1)OC(CC(*)=C1CCC(C)C)C2C1O*)C2=O 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Chemical group 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- -1 fatty acid ester Chemical class 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001394637A JP2003192590A (ja) | 2001-12-26 | 2001-12-26 | 抗癌剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001394637A JP2003192590A (ja) | 2001-12-26 | 2001-12-26 | 抗癌剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003192590A true JP2003192590A (ja) | 2003-07-09 |
| JP2003192590A5 JP2003192590A5 (enExample) | 2005-07-14 |
Family
ID=27601320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001394637A Pending JP2003192590A (ja) | 2001-12-26 | 2001-12-26 | 抗癌剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2003192590A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008020490A1 (en) * | 2006-08-17 | 2008-02-21 | Kansai Koso Co., Ltd. | Artocarpine derivative or artocarpine-like compound, and hair growth/restoration composition, skin-whitening cosmetic composition, pharmaceutical as anti-cancer, antiphlogistic/analgesic, antipyretic or antiallergic agent and pharmaceutical for treatment of pigmented skin lesion each comprising the same |
-
2001
- 2001-12-26 JP JP2001394637A patent/JP2003192590A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008020490A1 (en) * | 2006-08-17 | 2008-02-21 | Kansai Koso Co., Ltd. | Artocarpine derivative or artocarpine-like compound, and hair growth/restoration composition, skin-whitening cosmetic composition, pharmaceutical as anti-cancer, antiphlogistic/analgesic, antipyretic or antiallergic agent and pharmaceutical for treatment of pigmented skin lesion each comprising the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE80548B1 (en) | New compositions containing taxane derivatives | |
| EP0774255B1 (en) | Use of ursolic acid for the manufacture of a medicament for suppressing metastasis | |
| CN109675041A (zh) | 用于治疗癌症的系统、方法和制剂 | |
| WO2001072685B1 (en) | Polyamine analogues as cytotoxic agents | |
| KR20160064966A (ko) | 화학요법제 보조에 사용하는 의약 조성물 및 그 용도 | |
| JPH0430924B2 (enExample) | ||
| CA2124793C (en) | Use of creatine phosphate or phosphoenolpyruvic acid for the treatment of tumours | |
| CN105497091B (zh) | 一种用于抗癌的常山酮青蒿倍半萜内酯类化合物的组合物及其应用 | |
| AU2004220205A1 (en) | Antitumor effect potentiator and antitumor agent | |
| CN116284175A (zh) | 一种小分子化合物及其在制备治疗慢性肾脏病药物中的应用 | |
| WO2007048353B1 (en) | Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart diseases | |
| CN114522158A (zh) | 用于制备治疗肝癌药物的代谢物及其应用 | |
| JP2003192590A (ja) | 抗癌剤 | |
| WO1992004028A1 (en) | Antineoplastic effect potentiator and antineoplastic agent | |
| JP2025011312A (ja) | ｐ－ボロノフェニルアラニンを含有する注射液剤の析出防止方法 | |
| CN106854223B (zh) | 氮芥槲皮素衍生物及其制备方法和用途 | |
| WO2023088062A1 (zh) | 厚朴酚和/或和厚朴酚芳环氨基取代类衍生物的抗低氧/缺氧损伤用途及药物组合物 | |
| HUP0203790A2 (hu) | (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére | |
| KR20220166203A (ko) | 퇴행성 안질환의 예방 또는 치료용 약학적 조성물 | |
| EP3608313B1 (en) | 15-idene-14-deoxy-11,12-dehydroandrographolide derivative and application thereof in preparing anti-fibrosis drugs | |
| KR20210076863A (ko) | 니클로사마이드를 포함하는 섬유증의 예방 및 치료용 조성물 | |
| EP0005074A1 (en) | A material and composition for reducing blood pressure | |
| JPS61129124A (ja) | 抗腫瘍剤 | |
| JP2876224B2 (ja) | 新規美白剤 | |
| JP2005035951A (ja) | 腫瘍転移抑制剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041117 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041117 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7421 Effective date: 20080214 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080528 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080603 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080731 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080731 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090113 |